Deregulated PAD activity has, therefore, been shown to play an important role in inflammatory diseases such as RA, and significant effort has been devoted to investigating the potential clinical use of PAD-specific inhibitors for these conditions. The gene discussed is PADI4; the disease is rheumatoid arthritis.